The course of pain and dysphagia after radiofrequency ablation for Barrett’s esophagus-related neoplasia

Abstract

Background Radiofrequency ablation (RFA) is effective for eradication of Barrett’s esophagus (BE) neoplasia, but little is known on the course of pain and dysphagia after RFA. We aimed to describe the course of post-RFA symptoms and to identify possible associated risk factors.

Methods In this multicenter, observational cohort study, all RFA procedures registered in a prospective database were included. Patient and treatment characteristics were collected from medical records and patients self-registered post-procedural symptoms in electronic symptom diaries for 14 days. Mixed model regression was used for the analyses.

Results In total, 255 diaries were completed. Post-RFA pain was reported for 95 % (95 %CI 93–98) of procedures (median duration 14 days; 25th–75th percentiles [p25–p75] 11–14) and major pain for 64 % (95 %CI 58–69; median duration 8 days, p25–p75 3–13). Post-procedural pain significantly increased with BE length, younger age, and no prior ablation. Dysphagia was present after 83 % (95 %CI 79–88) of procedures (median duration 13 days, p25–p75 9–14). The risk of dysphagia decreased with age and increased when patients experienced more pain.

Conclusions RFA treatment for BE-related neoplasia seems a significant burden for patients, and post-procedural symptoms should be taken into account when counseling patients before starting endoscopic eradication therapy.

• References

• 1 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
• 2 Phoa KN, Pouw RE, van Vilsteren FGI. et al. Remission of Barrett’s esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104
• 3 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett’s Esophagus with Dysplasia. N Engl J Med 2009; 360: 2277-2288
• 4 Qumseya BJ, Wani S, Desai M. et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1086-1095
• 5 van Munster SN, Overwater A, Haidry R. et al. Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett’s esophagus: impact on treatment response and postprocedural pain. Gastrointest Endosc 2018; 88: 795-803
• 6 Persson J, Engström C, Bergquist H. et al. Validation of instruments for the assessment of dysphagia due to malignancy of the esophagus. Dis Esophagus 2019; 32: doy125
• 7 Myles PS, Myles DB, Galagher W. et al. Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state. Br J Anaesth 2017; 118: 424-429
• 8 Edwards LJ. Modern statistical techniques for the analysis of longitudinal data in biomedical research. Pediatr Pulmonol 2000; 30: 330-344
• 9 von Elm E, Altman DG, Egger M. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014; 12: 1495-1499
• 10 Desai M, Saligram S, Gupta N. et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc 2017; 85: 482-495
• 11 Fleischer DE, Overholt BF, Sharma VK. et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68: 867-876
• 12 De Paepe AL, Williams AC de C, Crombez G. Habituation to pain: a motivational-ethological perspective. Pain 2019; 160: 1693-1697
• 13 Lautenbacher S, Peters JH, Heesen M. et al. Age changes in pain perception: a systematic-review and meta-analysis of age effects on pain and tolerance thresholds. Neurosci Biobehav Rev 2017; 75: 104-113
• 14 Pouw RE, Klaver E, Phoa KN. et al. Radiofrequency ablation for low-grade dysplasia in Barrett’s esophagus: long-term outcome of a randomized trial. Gastrointest Endosc 2020; 92: 569-574
• 15 Pech O, Alqahtani SA. Update on endoscopic treatment of Barrett’s oesophagus and Barrett’s oesophagus-related neoplasia. Ther Adv Gastrointest Endosc 2020; 13: 2631774520935241
• 16 van Munster S, Nieuwenhuis E, Weusten BLAM. et al. Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period. Gut 2022; 71: 265-276
• 17 Wolfson P, Ho KMA, Wilson A. et al. Endoscopic eradication therapy for Barrett’s esophagus related neoplasia. A final 10 year report from the United Kingdom National Halo Radiofrequency Ablation Registry. Gastrointest Endosc 2022; 96: 223-233
• 18 Pouw RE, Künzli HT, Bisschops R. et al. Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett’s oesophagus: a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 2018; 3: 566-574